Clover Health Investments (CLOV) is poised for "strong" 2025 revenue guidance with the outlook for the medical loss ratio "less clear," UBS Securities said Monday in a report.
In Q4 results set for Thursday, "the focus will be on how the company's newfound growth will translate for MLR" and adjusted earnings before interest, taxes, depreciation and amortization, UBS said.
Growth for 2025 "was noted to have come largely from switchers, which should provide for improved economics" relative to new to Medicare Advantage members," UBS said.
The "relatively positive" Advance Medicare Advantage notice for 2026 may boost revenue in 2026, leaving the company on an "upward trajectory," the report said.
UBS raised its price target on Clover Health to $4.50 from $4 and maintained its neutral rating.
Price: 4.23, Change: -0.18, Percent Change: -3.98
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.